EARNEST Partners’s West Pharmaceutical WST Stock Holding History

EARNEST Partners’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-39	Closed	-$14.6K	–	1104
2023 Q3	$14.6K	Hold	39	–	–	﹤0.01%	552
2023 Q2	$14.9K	Hold	39	–	–	﹤0.01%	545
2023 Q1	$13.5K	Hold	39	–	–	﹤0.01%	557
2022 Q4	$9.18K	Hold	39	–	–	﹤0.01%	637
2022 Q3	$10K	Hold	39	–	–	﹤0.01%	597
2022 Q2	$12K	Hold	39	–	–	﹤0.01%	569
2022 Q1	$16K	Hold	39	–	–	﹤0.01%	543
2021 Q4	$18K	Hold	39	–	–	﹤0.01%	530
2021 Q3	$17K	Hold	39	–	–	﹤0.01%	529
2021 Q2	$14K	Hold	39	–	–	﹤0.01%	575
2021 Q1	$11K	Hold	39	–	–	﹤0.01%	616
2020 Q4	$11K	Hold	39	–	–	﹤0.01%	596
2020 Q3	$11K	Hold	39	–	–	﹤0.01%	546
2020 Q2	$9K	Hold	39	–	–	﹤0.01%	596
2020 Q1	$6K	Hold	39	–	–	﹤0.01%	639
2019 Q4	$6K	Buy	+39	New	+$5.68K	﹤0.01%	744
2018 Q4	–	Sell	-20	Closed	-$2K	–	1220
2018 Q3	$2K	Hold	20	–	–	﹤0.01%	1054
2018 Q2	$2K	Hold	20	–	–	﹤0.01%	1062
2018 Q1	$2K	Hold	20	–	–	﹤0.01%	1033
2017 Q4	$2K	Buy	+20	New	+$1.96K	﹤0.01%	1032
2017 Q1	–	Sell	-20	Closed	-$2K	–	916
2016 Q4	$2K	Buy	+20	New	+$1.57K	﹤0.01%	976

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

EARNEST Partners's WST Position: Q4 2023 in Review

EARNEST Partners sold out of West Pharmaceutical (WST) in Q4 2023, closing a stake of 39 shares — an estimated $14.6K sold.

EARNEST Partners first reported a position in WST in Q4 2016 and held it in 21 quarters. The position peaked at $18K in Q4 2021. 783 funds tracked by Wall St. Rank hold WST as of Q4 2023.

EARNEST Partners reported no remaining West Pharmaceutical position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 39 West Pharmaceutical shares in Q4 2023, an estimated $14.6K.
EARNEST Partners first reported a position in West Pharmaceutical in Q4 2016 and held it in 21 quarters.
EARNEST Partners's West Pharmaceutical position peaked at $18K in Q4 2021.
783 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.